With shares flat year-to-date, this indicates 20% upside lies ahead. JP Morgan's Cory Kasimov says the deal brings a solid commercial asset in-house, but at a high price. According to Kasimov, Trodelvy has blockbuster potential in multiple solid tumor indications- telling investors "this is the type of tangible deal Gilead needs to try and inject some much needed growth into its future outlook."